.30
  Price1.49%   -0.0046
(After Hours: .31 +0.0053 +1.74%)
Aug-10-22 06:08AM Why Is CarLotz Higher By More Than 30%: Here Are 28 Stocks Moving PremarketBenzinga
Aug-03-22 12:00PM All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to BuyZacks Investment Research
Jun-03-22 10:08AM Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022Benzinga
09:08AM Where ObsEva Stands With AnalystsBenzinga
May-27-22 04:01AM ObsEva Announces Corporate UpdatesGlobeNewswire Inc.
May-25-22 07:00AM ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple CongressesGlobeNewswire Inc.
01:00AM ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple CongressesGlobeNewswire Inc.
May-19-22 07:05AM ObsEva Announces Appointment of Annette Clancy as Chair of the Board of DirectorsGlobeNewswire Inc.
07:00AM ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022GlobeNewswire Inc.
May-19-22 01:05AM ObsEva Announces Appointment of Annette Clancy as Chair of the Board of DirectorsGlobeNewswire Inc.
01:00AM ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022GlobeNewswire Inc.
May-17-22 07:00AM ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswire Inc.
01:00AM ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswire Inc.
May-16-22 01:00AM ObsEva to Present at the H.C. Wainwright Global Investment 2022 ConferenceGlobeNewswire Inc.
May-12-22 01:00AM ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business UpdateGlobeNewswire Inc.
May-09-22 07:00AM ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting GlobeNewswire Inc.
01:00AM ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting GlobeNewswire Inc.
May-02-22 07:00AM ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical OfficerGlobeNewswire Inc.
01:00AM ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical OfficerGlobeNewswire Inc.
Apr-26-22 10:04AM Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2022Benzinga
08:58AM 5 Hot Penny Stocks To Watch With Premarket Momentum & NewsPennyStocks
Apr-25-22 07:00AM ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine FibroidsGlobeNewswire Inc.
01:00AM ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine FibroidsGlobeNewswire Inc.
Apr-07-22 01:00AM ObsEva Annual General Meeting 2022GlobeNewswire Inc.
Mar-31-22 07:00AM ObsEva Annual Report 2021GlobeNewswire Inc.
01:00AM ObsEva Annual Report 2021GlobeNewswire Inc.
Mar-28-22 10:05AM Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2022Benzinga
Mar-22-22 02:00AM ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated PainGlobeNewswire Inc.
Mar-10-22 01:00AM ObsEva Announces Year End 2021 Financial Results and Provides Corporate UpdateGlobeNewswire Inc.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.
Cap:    |  Volume (24h):